Diagnostic technologies for identification of SARS-CoV-2 from human nasal, buccal, or saliva samples.
Sixty-nine (69) Entries were received from an international community of corporations, universities and government labs. This community included a total of 50 non-traditional institutions (primarily small organizations with less than 20 employees) featuring prototype level solutions. The aim of this call was rapid and efficient diagnosis, with emphasis on rapid point of care testing and diagnostics. While submissions that required saliva or nasal samples were dominant, seven (7) submissions were focused on breath analysis with one submission involving analysis of chest x-rays. Functionally, all submissions categorized into 4 main technical groups: 1) nucleic acid amplification; 2) biosensors; 3) optical spectroscopy; and 3) other innovative methods.
Highlights from the pool of Entries include:
To learn more about TechConnect Ventures' Innovation Sprints please contact Nick Kacsandi at
*Participation by any United States Federal Agency in any TechConnect activity or event does not constitute an expressed or implied endorsement of any cosponsor, donor, grantee, contractor or participant’s opinions, products, or services.